Anrukinzumab
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | IL13 |
| Identifiers | |
| CAS Number | 910649-32-0  |
| ATC code | none |
| ChemSpider | none |
| UNII | OU46IGC49F  |
| Chemical data | |
| Formula | C6452H9954N1714O2024S46 |
| Molar mass | 145.4 kg/mol |
| (what is this?) (verify) |
|
Anrukinzumab (IMA-638[1]) is a humanized monoclonal antibody designed for the treatment of asthma.[2]
Anrukinzumab was developed by Wyeth.
References[edit]
- ^ "Wyeth.com | Complete Project Listing". Wyeth. 2008. Archived from the original on June 12, 2008. Retrieved November 19, 2008.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council: Anrukinzumab, American Medical Association.
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
